Washington DC (PRWEB) April 10, 2012
World Molecular Imaging Society (WMIS) is publishing an interview of Alex Kleinman of Bioscan on its e-zine. The interview focused on the strategic issues and developments in the molecular imaging field. Mr. Kleinman is the VP of Marketing and Business Development at preclinical imaging leader, Bioscan, Inc., and a leading expert in the molecular imaging industry.
"Mr. Kleinman's interview provides deep and insightful look at the state of the molecular imaging industry. His strategic orientation will resonate well with all those who are involved in promoting the field." said Dr. Juri Gelovani, President of WMIS. "Mr. Kleinman's interview addresses several major issues that will impact the growth of the field. I would highly recommend to the entire molecular imaging community to read and benefit from Mr. Kleinman's observations." Mr. Gelovani added.
"We are thrilled to publish Mr. Kleinman's interview. Our society is actively helping both industry and academia to smash silos and lead the innovation convergence in the molecule imaging field. I am so happy that we are able to bring executive leaders such as Mr. Kleinman to a growing community of thousands of molecular imaging professionals all over the world who are now all connecting on the WMIS platform." said Kim Pierce Executive Director of WMIS.
Mr. Kleinman's interview can be read on http://www.wmis.org. It is featured as the cover story of the weekly http://www.wmis.org e-magazine.
WMIS is the world's most innovative and leading society in molecular imaging and molecular medicine. With the rise of the molecular imaging industry and the associated research, WMIS is the only organization that is connecting all the dots in the industry and is working to bring all stakeholders together by Smashing the Silos and Leading Innovation Convergence in molecular medicine; both for practitioners and researchers, who are defining the future of molecular imaging, WMIS enhances the potential and applications of innovation.
Bioscan is a leading supplier of preclinical, nano-tomographic molecular imaging solutions that enable groundbreaking life sciences research. Preclinical imaging uses molecular biomarkers in animals to conduct in vivo studies that generate more relevant, consistent biological data while reducing research cost and complexity. Bioscan’s innovative nuclear (PET & SPECT), optical, X-Ray CT and MRI imaging tools are used by more than 100 leading academic and government research institutions and life sciences companies worldwide to improve their disease, drug discovery and development research. The unique imaging performance enabled by Bioscan‘s patented technologies makes it possible to translate research protocols and results directly from animal models of diseases to human clinical trials, enabling faster, more efficient development of new therapies. For more information about Bioscan, please visit http://www.bioscan.com.